Targets › SRD5A2
7 programs from 6 companies in 22 trials: 15 Phase 2, 4 Phase 3, 3 Phase 4; Oncology, Respiratory, Immunology; next expected readout Nov 2026.
Catalyzes the irreversible stereospecific reduction of the delta 4,5 bond (double bond between carbons 4 and 5) of various 3-oxo steroids (3-keto steroids) producing their 5alpha dihydro-3-oxo forms. Converts testosterone into 5-alpha-dihydrotestosterone (DHT), the most active androgen in the prostate, as it is the preferred ligand for androgen receptor (AR) transactivation, making this reaction a key step in male…. (UniProt, P31213)
Open in Phaseline: the race on SRD5A2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Turku University Hospital | Dutasteride Steroid 5-alpha-reductase inhibitor | SRD5A1, SRD5A2, SRD5A3 | Phase 4 | Prostatic Hyperplasia | Dec 2026 |
| Turku University Hospital | Finasteride Steroid 5-alpha-reductase 2 inhibitor | SRD5A2 | Phase 4 | Prostatic Hyperplasia | Dec 2026 |
| VA Office of Research and Development | Finasteride Steroid 5-alpha-reductase 2 inhibitor | SRD5A2 | Phase 4 | Sleep Apnea | Jul 2027 |
| Triple Hair | TH07 Fixed combination of 5-alpha reductase inhibitor (finasteride), alpha-adrenergic agonist ( | SRD5A2, PTGFR | Phase 3 | Androgenic Alopecia | Dec 2027 |
| Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair | Abiraterone Cytochrome P450 17A1 inhibitor; Androgen Receptor antagonist; Steroid 5-alpha-reductase inhibitor | CYP17A1, AR, SRD5A1, SRD5A2, SRD5A3 | Phase 2 | Prostate Cancer; Metastatic Castration-resistant Prostate Cancer (mCRPC); Castration Levels of Testosterone; Advanced Prostate Adenocarcinoma … | Nov 2026 |
| Radboud University Medical Center | Dutasteride Steroid 5-alpha-reductase inhibitor | SRD5A1, SRD5A2, SRD5A3 | Phase 2 | Salivary Duct Carcinoma | Sep 2027 |
| Paul Toren | Dutasteride Steroid 5-alpha-reductase inhibitor | SRD5A1, SRD5A2, SRD5A3 | Phase 2 | Bladder Cancer | Apr 2030 |
Prostate Cancer (6) Prostatic Hyperplasia (2) Metastatic Prostate Cancer (2) Bladder Cancer (1) Sleep Apnea (1) Metastatic Castration-resistant Prostate Cancer (mCRPC) (1) Castration Levels of Testosterone (1) Advanced Prostate Adenocarcinoma (1) Prostate Cancer (Diagnosis) (1) Metastatic Castration-resistant Prostate Cancer (1) Prostate Cancer Metastatic Disease (1) Salivary Gland Carcinoma (1)
small molecule (7)
Turku University Hospital (2) Paul Toren (1) VA Office of Research and Development (1) Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair (1) Radboud University Medical Center (1) Triple Hair (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.